ClinicalTrials.gg
Active, not recruitingNCT07048197Updated Sep 4, 2026

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

A Phase 1/2 interventional study of Rapcabtagene autoleucel in Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 12 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Arthritis, Rheumatoid by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.

Planned enrollment
28th of 30
27 · median 98
Started
2025
with 1 other
Phase 1/2
7 of 30
none open now
Registered
29th of 30
by date

Among the 30 studies in Arthritis, Rheumatoid by Novartis, this one is the 28th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 1/2, and was the 29th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 30 studies in Arthritis, Rheumatoid by Novartis is open now. Recruiting first, the newest first:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Arthritis, Rheumatoid by Novartis, or all of them as a file.
02

Study summary

A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease

Read the detailed description

The study is intended to assess safety, cellular kinetics and any early sign for efficacy of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis (D2T RA) and severe, refractory Sjogren's disease (srSjD) with organ involvement.

03

Conditions studied

  • Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

Keywords

  • CAR-T,
  • YTB323,
  • rapcabtagene autoleucel,
  • D2T RA,
  • srSjD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study
  • Men and women aged ≥ 18 years and ≤ 75 years at Screening For RA only
  • Diagnosis of rheumatoid arthritis
  • Treatment failure of standard of care therapies
  • Active disease For SjD only
  • Diagnosis of Sjogren's disease
  • Active disease

Exclusion criteria

Exclusion Criteria:

  • at Screening of ≤17 or ≥ 40 kg/m2
  • active, opportunistic, chronic or recurrent infection
  • Sexually active males unwilling to use a condom during intercourse from the time enrollment
  • Women of , unless they are using a highly effective method of starting from the time of enrollment
  • Female participants who are pregnant, breastfeeding or intending to conceive during the course of the study
  • Inadequate organ function during screening
  • History of lymphoproliferative disease or any known or history of malignancy
  • History of bone marrow/hematopoietic stem cell or solid organ transplantation
  • Any psychiatric condition or disability making compliance with treatment or impossible

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Rapcabtagene autoleucel-rheumatoid arthritis

    Single infusion of Rapcabtagene autoleucel in participants with rheumatoid arthritis

    Biological: Rapcabtagene autoleucel

  • Experimental
    Rapcabtagene autoleucel- Sjögren's Disease

    Single infusion of Rapcabtagene autoleucel in participants with Sjögren's Disease

    Biological: Rapcabtagene autoleucel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Safety parameters include vital signs, adverse events, laboratory parameters and ECG evaluation

    Time frame: 24 months

Secondary outcomes

  1. Pharmacokinetic (PK) parameter: Cmax

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax).

    Time frame: 24 months

  2. PK parameter: Tmax

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax).

    Time frame: 24 months

  3. PK parameter: T1/2

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2).

    Time frame: 24 months

  4. PK parameter: Clast

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast).

    Time frame: 24 months

  5. PK parameter: Tlast

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast).

    Time frame: 24 months

  6. PK parameter: AUC

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC).

    Time frame: 24 months

07

Study locations

12 sites
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2028, 40 months after the start.

Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Jun 20, 2025
Primary completionEst.
Nov 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07048197
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
Jun 20, 2025
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rapcabtagene autoleucel

Start the discussion